SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Laurent, G. Articles by Jaffrézou, J.-P. Search for Related Content PubMed PubMed Citation Articles by Laurent, G. Articles by Jaffrézou, J.-P. Related Collections Neoplasia Signal Transduction Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2001, Vol. 98, No. 4, pp. 913-924 REVIEW ARTICLE Signaling pathways activated by daunorubicin Guy Laurent and Jean-Pierre Jaffrézou From the INSERM E9910, Institut Claudius Régaud, Toulouse, France; and the Service d'Hématologie, Centre Hospitalier Universitaire Purpan, Toulouse, France. The anthracycline daunorubicin is widely used in the treatment of acute nonlymphocytic leukemia. The drug has, of course, been the object of intense basic research, as well as preclinical and clinical study. As reviewed in this article, evidence stemming from this research clearly demonstrates that cell response to daunorubicin is highly regulated by multiple signaling events, including a sphingomyelinase-initiated sphingomyelin-ceramide pathway, mitogen-activated kinase and stress-activated protein/c-Jun N-terminal kinase activation, transcription factors such as nuclear factor B, as well as the Fas/Fas-ligand system. These pathways are themselves influenced by a number of lipid products (diacylglycerol, sphingosine-1 phosphate, and glucosyl ceramide), reactive oxygen species, oncogenes (such as the tumor suppressor gene p53), protein kinases (protein kinase C and phosphoinositide-3 kinase), and external stimuli (hematopoietic growth factors and the extracellular matrix). In light of the complexity and diversity of these observations, a comprehensive review has been attempted toward the understanding of their individual implication (and regulation) in daunorubicin-induced signaling. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Gausdal, B. T. Gjertsen, E. McCormack, P. Van Damme, R. Hovland, C. Krakstad, O. Bruserud, K. Gevaert, J. Vandekerckhove, and S. O. Doskeland Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death Blood, March 1, 2008; 111(5): 2866 - 2877. [Abstract] [Full Text] [PDF] S. Duan, W. K. Bleibel, R. S. Huang, S. J. Shukla, X. Wu, J. A. Badner, and M. E. Dolan Mapping Genes that Contribute to Daunorubicin-Induced Cytotoxicity Cancer Res., June 1, 2007; 67(11): 5425 - 5433. [Abstract] [Full Text] [PDF] C. G. Pham, C. Bubici, F. Zazzeroni, J. R. Knabb, S. Papa, C. Kuntzen, and G. Franzoso Upregulation of Twist-1 by NF-{kappa}B Blocks Cytotoxicity Induced by Chemotherapeutic Drugs Mol. Cell. Biol., June 1, 2007; 27(11): 3920 - 3935. [Abstract] [Full Text] [PDF] Y. Shi, D. White, L. He, R. L. Miller, and D. E. Spaner Toll-like Receptor-7 Tolerizes Malignant B Cells and Enhances Killing by Cytotoxic Agents Cancer Res., February 15, 2007; 67(4): 1823 - 1831. [Abstract] [Full Text] [PDF] M. Mattia, V. Gottifredi, K. McKinney, and C. Prives p53-Dependent p21 mRNA Elongation Is Impaired when DNA Replication Is Stalled Mol. Cell. Biol., February 15, 2007; 27(4): 1309 - 1320. [Abstract] [Full Text] [PDF] O. Beyne-Rauzy, N. Prade-Houdellier, C. Demur, C. Recher, J. Ayel, G. Laurent, and V. Mansat-De Mas Tumor necrosis factor-{alpha} inhibits hTERT gene expression in human myeloid normal and leukemic cells Blood, November 1, 2005; 106(9): 3200 - 3205. [Abstract] [Full Text] [PDF] R. Avellino, S. Romano, R. Parasole, R. Bisogni, A. Lamberti, V. Poggi, S. Venuta, and M. F. Romano Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells Blood, August 15, 2005; 106(4): 1400 - 1406. [Abstract] [Full Text] [PDF] L. Catley, Y.-T. Tai, R. Shringarpure, R. Burger, M. T. Son, K. Podar, P. Tassone, D. Chauhan, T. Hideshima, L. Denis, et al. Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma Cancer Res., December 1, 2004; 64(23): 8746 - 8753. [Abstract] [Full Text] [PDF] L. Tourneur, S. Delluc, V. Levy, F. Valensi, I. Radford-Weiss, O. Legrand, J. Vargaftig, C. Boix, E. A. Macintyre, B. Varet, et al. Absence or Low Expression of Fas-Associated Protein with Death Domain in Acute Myeloid Leukemia Cells Predicts Resistance to Chemotherapy and Poor Outcome Cancer Res., November 1, 2004; 64(21): 8101 - 8108. [Abstract] [Full Text] [PDF] S. Wang, E. A. Konorev, S. Kotamraju, J. Joseph, S. Kalivendi, and B. Kalyanaraman Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms: INTERMEDIACY OF H2O2- AND p53-DEPENDENT PATHWAYS J. Biol. Chem., June 11, 2004; 279(24): 25535 - 25543. [Abstract] [Full Text] [PDF] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF] S. Grazide, A.-D. Terrisse, S. Lerouge, G. Laurent, and J.-P. Jaffrezou Cytoprotective Effect of Glucosylceramide Synthase Inhibition against Daunorubicin-induced Apoptosis in Human Leukemic Cell Lines J. Biol. Chem., April 30, 2004; 279(18): 18256 - 18261. [Abstract] [Full Text] [PDF] S. FOGLI, P. NIERI, and M. C. BRESCHI The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage FASEB J, April 1, 2004; 18(6): 664 - 675. [Abstract] [Full Text] [PDF] A. Hueber, M. Weller, G. Welsandt, N. Kociok, B. Kirchhof, and P. Esser Characterization of Daunorubicin-Induced Apoptosis in Retinal Pigment Epithelial Cells: Modulation by CD95L Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2851 - 2857. [Abstract] [Full Text] [PDF] G. M. Hur, J. Lewis, Q. Yang, Y. Lin, H. Nakano, S. Nedospasov, and Z.-g. Liu The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation Genes & Dev., April 1, 2003; 17(7): 873 - 882. [Abstract] [Full Text] [PDF] V. M.-D. Mas, H. Hernandez, I. Plo, C. Bezombes, N. Maestre, A. Quillet-Mary, R. Filomenko, C. Demur, J.-P. Jaffrezou, and G. Laurent Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin Blood, February 15, 2003; 101(4): 1543 - 1550. [Abstract] [Full Text] [PDF] M. L. Guzman, C. F. Swiderski, D. S. Howard, B. A. Grimes, R. M. Rossi, S. J. Szilvassy, and C. T. Jordan Preferential induction of apoptosis for primary human leukemic stem cells PNAS, December 10, 2002; 99(25): 16220 - 16225. [Abstract] [Full Text] [PDF] C. Bezombes, A. de Thonel, A. Apostolou, T. Louat, J.-P. Jaffrezou, G. Laurent, and A. Quillet-Mary Overexpression of Protein Kinase Czeta Confers Protection Against Antileukemic Drugs by Inhibiting the Redox-Dependent Sphingomyelinase Activation Mol. Pharmacol., December 1, 2002; 62(6): 1446 - 1455. [Abstract] [Full Text] [PDF] Abstracts of Presentations at the Meeting of the Association of Clinical Scientists in Salt Lake City, UT, on 8 to 11 May 2002 Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 312 - 333. [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020